By CEDARS-SINAI: For Complete Post, Click Here…
HOME HEALTH NEWS
87% Survival – New Combined Therapy Greatly Improves Prostate Cancer Survival
TOPICS:CancerCedars-Sinai Medical CenterProstate CancerRadiation Therapy
By CEDARS-SINAI JULY 16, 2022
Natural Killer Cell Destorying Cancer Cell Illustration
The combination therapy patient group underwent pelvic lymph node radiation and androgen deprivation treatment, as well as salvage prostate bed radiation. Over 87 percent of these patients had five-year freedom from cancer progression.
A Cedars-Sinai cancer study indicates improved survival following a combination of hormone therapy and pelvic lymph node treatment
A combination of androgen deprivation therapy—a common hormone injection—and pelvic lymph node radiotherapy prevented prostate cancer from therapy in nearly 90% of clinical trial participants for five years, according to a ground-breaking study from Cedars-Sinai Cancer. The results were recently published in the peer-reviewed journal The Lancet.
The research also demonstrates that individuals with prostate cancer who did not get pelvic lymph node radiotherapy or androgen restriction treatment had a five-year survival rate of 70%.
